98 related articles for article (PubMed ID: 17615198)
1. Economist says NICE should approve fewer costly drugs.
O'Dowd A
BMJ; 2007 Jul; 335(7609):11. PubMed ID: 17615198
[No Abstract] [Full Text] [Related]
2. NICE and the challenge of cancer drugs.
Raftery J
BMJ; 2009 Jan; 338():b67. PubMed ID: 19141502
[No Abstract] [Full Text] [Related]
3. NICE is too generous in approving drugs, analysis says.
Hawkes N
BMJ; 2015 Feb; 350():h955. PubMed ID: 25698770
[No Abstract] [Full Text] [Related]
4. Successful procurement. A licence to spend money?
Millar B
Health Serv J; 1997 Jun; 107(5558):suppl 1-5. PubMed ID: 10168724
[No Abstract] [Full Text] [Related]
5. NICE appraisals should be everybody's business.
Wells J; Cheong-Leen C
BMJ; 2007 May; 334(7600):936-8. PubMed ID: 17478847
[TBL] [Abstract][Full Text] [Related]
6. Speeding up access to new drugs threatens evidence based medicine, says health economist.
Hawkes N
BMJ; 2016 Jan; 352():i263. PubMed ID: 26772965
[No Abstract] [Full Text] [Related]
7. Health Technology Assessment. NICE goes global.
Hawkes N
BMJ; 2009 Jan; 338():b103. PubMed ID: 19176677
[No Abstract] [Full Text] [Related]
8. Comparative effectiveness research: NICE for the NHS, but false starts for the US.
Lyles A
Clin Ther; 2008 Sep; 30(9):1702-3. PubMed ID: 18840376
[No Abstract] [Full Text] [Related]
9. NICE or nasty? National Institute of Clinical Excellence.
Johnson SA
Clin Oncol (R Coll Radiol); 2002 Apr; 14(2):86-8. PubMed ID: 12069132
[No Abstract] [Full Text] [Related]
10. NICE: friend and foe.
Low E
Nat Clin Pract Oncol; 2007 Mar; 4(3):135. PubMed ID: 17327853
[No Abstract] [Full Text] [Related]
11. Experts condemn "flawed" NICE process over its rejection of prostate cancer drug.
O'Dowd A
BMJ; 2014 Aug; 349():g5224. PubMed ID: 25139515
[No Abstract] [Full Text] [Related]
12. More drugs pass the NICE test.
MacDonald R
BMJ; 2000 Oct; 321(7265):853. PubMed ID: 11021859
[No Abstract] [Full Text] [Related]
13. New Cancer Drugs Fund is flawed without NICE reform, says Roche.
Hawkes N
BMJ; 2016 Jul; 354():i4216. PubMed ID: 27473207
[No Abstract] [Full Text] [Related]
14. Patients are still not receiving NICE approved drugs, report says.
Mooney H
BMJ; 2012 Oct; 345():e7045. PubMed ID: 23078963
[No Abstract] [Full Text] [Related]
15. From NCE to NICE: the role of pharmacoeconomics.
Hughes DA
Br J Clin Pharmacol; 2010 Sep; 70(3):317-9. PubMed ID: 20716229
[No Abstract] [Full Text] [Related]
16. Sir Michael Rawlins on being NICE--and fair--about drug development and availability. Interview by Daniel Clarke.
Rawlins SM
Drug Discov Today; 2005 Mar; 10(6):383-6. PubMed ID: 15808816
[No Abstract] [Full Text] [Related]
17. NICE uses wrong comparator to assess cost effectiveness of new drugs, report says.
Hawkes N
BMJ; 2014 Mar; 348():g2134. PubMed ID: 24647344
[No Abstract] [Full Text] [Related]
18. MS specialist role deserves proper recognition from NICE, says charity.
Kleebauer A
Nurs Stand; 2014 Oct; 29(7):11. PubMed ID: 25315532
[TBL] [Abstract][Full Text] [Related]
19. How New Zealand has contained expenditure on drugs.
Cumming J; Mays N; Daubé J
BMJ; 2010 May; 340():c2441. PubMed ID: 20483927
[No Abstract] [Full Text] [Related]
20. Medicines regulation and the pharmaceutical industry.
Breckenridge A; Woods K
BMJ; 2005 Oct; 331(7520):834-6. PubMed ID: 16210285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
